These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 15777203)
1. Signal transduction by IL-2 and its receptors as target in treatment of rheumatoid arthritis. Kozanidou VI; Theocharis AD; Georgiadis A; Voulgari PV; Drosos AA; Karamanos NK Curr Drug Targets Immune Endocr Metabol Disord; 2005 Mar; 5(1):41-50. PubMed ID: 15777203 [TBL] [Abstract][Full Text] [Related]
2. Newer immunosuppressive drugs: their potential role in rheumatoid arthritis therapy. Drosos AA Drugs; 2002; 62(6):891-907. PubMed ID: 11929337 [TBL] [Abstract][Full Text] [Related]
3. [Rheumatoid arthritis and cytokines]. Kaneko S; Kondo Y; Yokosawa M; Sumida T Nihon Rinsho; 2016 Jun; 74(6):913-8. PubMed ID: 27311178 [TBL] [Abstract][Full Text] [Related]
4. [Rheumatoid arthritis: new developments in the pathogenesis with special reference to synovial fibroblasts]. Seemayer CA; Distler O; Kuchen S; Müller-Ladner U; Michel BA; Neidhart M; Gay RE; Gay S Z Rheumatol; 2001 Oct; 60(5):309-18. PubMed ID: 11759230 [TBL] [Abstract][Full Text] [Related]
5. Targeted therapy in rheumatoid arthritis. Köller MD Wien Med Wochenschr; 2006 Jan; 156(1-2):53-60. PubMed ID: 16465614 [TBL] [Abstract][Full Text] [Related]
6. The prospects for targeting FcR as a novel therapeutic strategy in rheumatoid arthritis. Wu Y; Pan W; Hu X; Zhang A; Wei W Biochem Pharmacol; 2021 Jan; 183():114360. PubMed ID: 33301760 [TBL] [Abstract][Full Text] [Related]
7. Th17 Cells in Immunopathogenesis and treatment of rheumatoid arthritis. Azizi G; Jadidi-Niaragh F; Mirshafiey A Int J Rheum Dis; 2013 Jun; 16(3):243-53. PubMed ID: 23981743 [TBL] [Abstract][Full Text] [Related]
8. Rheumatoid arthritis: Recent advances on its etiology, role of cytokines and pharmacotherapy. Alam J; Jantan I; Bukhari SNA Biomed Pharmacother; 2017 Aug; 92():615-633. PubMed ID: 28582758 [TBL] [Abstract][Full Text] [Related]
9. Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes. Hot A; Miossec P Ann Rheum Dis; 2011 May; 70(5):727-32. PubMed ID: 21345813 [TBL] [Abstract][Full Text] [Related]
10. IL-33 in rheumatoid arthritis: potential role in pathogenesis and therapy. Xu WD; Zhang M; Zhang YJ; Ye DQ Hum Immunol; 2013 Sep; 74(9):1057-60. PubMed ID: 23800433 [TBL] [Abstract][Full Text] [Related]
11. Targeting interleukin-2 as a treatment for psoriasis. Salim A; Emerson R Curr Opin Investig Drugs; 2001 Nov; 2(11):1546-8. PubMed ID: 11763155 [TBL] [Abstract][Full Text] [Related]
12. Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis. Benedetti G; Miossec P Eur J Immunol; 2014 Feb; 44(2):339-47. PubMed ID: 24310226 [TBL] [Abstract][Full Text] [Related]
13. Gene therapy for rheumatoid arthritis. Lessons from animal models, including studies on interleukin-4, interleukin-10, and interleukin-1 receptor antagonist as potential disease modulators. van de Loo FA; van den Berg WB Rheum Dis Clin North Am; 2002 Feb; 28(1):127-49. PubMed ID: 11840694 [TBL] [Abstract][Full Text] [Related]
14. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis. Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663 [TBL] [Abstract][Full Text] [Related]
15. The interleukin-2/interleukin-2 receptor system: structural, immunological, and clinical features. Semenzato G; Pizzolo G; Zambello R Int J Clin Lab Res; 1992; 22(3):133-42. PubMed ID: 1520910 [TBL] [Abstract][Full Text] [Related]
16. Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis. van Nieuwenhuijze AE; van de Loo FA; Walgreen B; Bennink M; Helsen M; van den Bersselaar L; Wicks IP; van den Berg WB; Koenders MI Arthritis Res Ther; 2015 Jun; 17(1):163. PubMed ID: 26081345 [TBL] [Abstract][Full Text] [Related]
17. Interleukin-22 and rheumatoid arthritis: emerging role in pathogenesis and therapy. Xie Q; Huang C; Li J Autoimmunity; 2015 Mar; 48(2):69-72. PubMed ID: 25483133 [TBL] [Abstract][Full Text] [Related]
18. Kirenol exerts a potent anti-arthritic effect in collagen-induced arthritis by modifying the T cells balance. Lu Y; Xiao J; Wu ZW; Wang ZM; Hu J; Fu HZ; Chen YY; Qian RQ Phytomedicine; 2012 Jul; 19(10):882-9. PubMed ID: 22673798 [TBL] [Abstract][Full Text] [Related]
19. Interleukin-6, soluble interleukin-2-receptor and soluble interleukin-6-receptor in sera of patients with rheumatoid arthritis: influences of disease activity and drug therapy. Franke S; Herrmann D; Hein G; Müller A; Stein G Eur J Med Res; 1997 Sep; 2(9):401-6. PubMed ID: 9300938 [TBL] [Abstract][Full Text] [Related]
20. IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. Mori T; Miyamoto T; Yoshida H; Asakawa M; Kawasumi M; Kobayashi T; Morioka H; Chiba K; Toyama Y; Yoshimura A Int Immunol; 2011 Nov; 23(11):701-12. PubMed ID: 21937456 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]